Rothschild Investment Corp IL lessened its stake in Pfizer Inc. (NYSE:PFE) by 1.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,001 shares of the biopharmaceutical company’s stock after selling 2,423 shares during the quarter. Pfizer comprises approximately 1.1% of Rothschild Investment Corp IL’s investment portfolio, making the stock its 21st biggest holding. Rothschild Investment Corp IL’s holdings in Pfizer were worth $8,744,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after purchasing an additional 6,785,335 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Pfizer by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company’s stock valued at $2,281,563,000 after purchasing an additional 1,881,570 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Pfizer by 1.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 61,720,550 shares of the biopharmaceutical company’s stock valued at $2,190,462,000 after purchasing an additional 889,094 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Pfizer by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock valued at $1,674,223,000 after purchasing an additional 4,998,981 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of Pfizer by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock valued at $1,431,069,000 after purchasing an additional 1,671,311 shares during the last quarter. Hedge funds and other institutional investors own 68.91% of the company’s stock.

Pfizer stock opened at $44.06 on Friday. Pfizer Inc. has a fifty-two week low of $33.20 and a fifty-two week high of $44.19. The company has a market cap of $257.52 billion, a P/E ratio of 16.63, a PEG ratio of 2.19 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business had revenue of $13.47 billion for the quarter, compared to analyst estimates of $13.30 billion. During the same quarter last year, the firm earned $0.67 EPS. Pfizer’s quarterly revenue was up 4.4% compared to the same quarter last year. analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date was Thursday, August 2nd. Pfizer’s payout ratio is currently 51.32%.

In other Pfizer news, CEO Ian C. Read sold 486,753 shares of Pfizer stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $37.36, for a total value of $18,185,092.08. Following the transaction, the chief executive officer now owns 1,145,693 shares of the company’s stock, valued at $42,803,090.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Loretta V. Cangialosi sold 26,814 shares of Pfizer stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the completion of the transaction, the vice president now directly owns 102,360 shares in the company, valued at approximately $4,110,777.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 761,230 shares of company stock worth $29,054,690. Insiders own 0.06% of the company’s stock.

PFE has been the topic of several recent research reports. BMO Capital Markets raised their target price on shares of Pfizer from $42.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, August 1st. Morgan Stanley reaffirmed a “buy” rating and issued a $43.00 target price on shares of Pfizer in a research note on Monday, June 11th. Jefferies Financial Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, July 31st. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $42.00 target price on shares of Pfizer in a research note on Wednesday, July 11th. Finally, Barclays set a $40.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 29th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $41.89.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: Should You Consider an Index Fund?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.